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Abstract
Background: Nanoparticles hold considerable promise for
aerosol-based intraperitoneal delivery in patients with
carcinomatosis. Recently, results from preclinical and
early clinical trials suggested that albumin-bound pacli-
taxel (ABP, Abraxane™) may result in superior efficacy
in the treatment of peritoneal metastases (PM) compared
to the standard solvent-based paclitaxel formulation
(Taxol™). Here, we propose a phase I study of pressur-
ized intraperitoneal aerosol chemotherapy (PIPAC) using
ABP in patients with upper Gastrointestinal, breast, or
ovarian cancer.
Methods: Eligible patients with advanced, biopsy-proven
PM from ovarian, breast, gastric, hepatobiliary, or pan-
creatic origin will undergo three PIPAC treatments using
ABP with a 4-week interval. The dose of ABP will be
escalated from 35 to 140mg/m² using a Bayesian approach
until the maximally tolerated dose is determined. The
primary end point is dose-limiting toxicity. Secondary
analyses include surgical morbidity, non-access rate, phar-
macokinetic and pharmacodynamic analyses, quality of
life, and exploratory circulating biomarker analyses.
Discussion: ABP holds considerable promise for intraper-
itoneal aerosol delivery. The aim of this study is to deter-
mine the dose level for future randomized phase II trials
using ABP in PIPAC therapy.
Trial registration: This trial is registered as EudraCT:
2017-001688-20 and Clinicaltrials.gov: NCT03304210.
Keywords: Abraxane, aerosol, albumin, carcinomatosis,
intraperitoneal, pressurized intraperitoneal aerosol
chemotherapy (PIPAC).
Introduction
The introduction of cytoreductive surgery and hyperther-
mic intraperitoneal chemoperfusion (HIPEC) has
improved the outcome of patients with peritoneal carci-
nomatosis from GI and ovarian origin [1, 2]. However, a
significant proportion of these patients are not amenable
to surgery due to extensive and/or irresectable disease.
Recently, the technique of laparoscopic (pressurized)
intraperitoneal (IP) aerosol chemotherapy (PIPAC) was
introduced in clinical practice [3, 4]. During laparoscopy,
chemotherapy is delivered as an aerosol, generated by
a dedicated micropump connected to a high-pressure
injector. Advantages of PIPAC include minimal patient
discomfort, possibility of repeated delivery, potential to
combine with systemic treatment, and possibility to assess
pathological response of peritoneal disease by serial biop-
sies. A recent prospective cohort study in women with
peritoneal carcinomatosis (84% ovarian cancer) showed
that repeated PIPAC resulted in an objective response
(histological regression after the first procedure) in 76%,
a significant decrease in peritoneal cancer index, and a
significantly decreased ascites volume [5]. Also, EORTC
QLQ-30+ 3 scores for global physical health, nausea/
vomiting, appetite loss, and constipation improved during
therapy.
In theory, any cancer drug may be delivered IP as an
aerosol. Because of their activity profile and molecular
size, the taxanes are ideal candidates for IP
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administration. The potential of Taxol™ for IP adminis-
tration is, however, limited by the local toxicity and
potential of hypersensitivity reactions associated with
the Cremophor EL™ component. Abraxane™ (Celgene)
is a novel 130 nm, albumin-bound (nab™) nanoparticle
formulation of paclitaxel (albumin-bound paclitaxel
[ABP]) which has demonstrated activity in metastatic
breast, pancreatic, and non-small-cell lung cancer [6].
Preclinical studies have demonstrated that IP adminis-
tration of nano- and microsized formulations of pacli-
taxel results in superior antitumor activity against
mouse ovarian cancer (OC) xenografts compared to
intravenous administration [7]. In a recent study using
an HIPEC model in the rabbit, peritoneal tissue concen-
trations after IP ABP were five times higher compared to
IP Taxol [8]. IP catheter-based delivery of Abraxane was
recently studied in a phase I clinical trial in advanced
carcinomatosis patients [9]. The maximally tolerated
dose (MTD) of IP nab-paclitaxel was140mg/m2; dose-
limiting toxicities (DLTs) included grade 3 neutropenia
resulting in treatment delay > 15 days, grade 3 abdom-
inal pain, and grade 4 neutropenia > 7 days. Over the
four-dose levels, there was a ~150-fold pharmacokinetic
(PK) advantage (AUCip/AUCplasma) with low intra-patient
variability.
Based on the above considerations, we hypothesize
that PIPAC with ABP is a rational strategy to test in
patients with unresectable peritoneal carcinomatosis
(PC) from ovarian, breast, or upper GI origin. Here, we
propose a study protocol of a phase I dose-escalation
study with several translational research end points.
Methods
General design
This is a multicenter, first-in-human phase I dose-escalation study to
explore the safety of PIPAC using ABP in patients with unresectable
peritoneal carcinomatosis.
End points
The primary end point of the study is the MTD of ABP, administered
three times every 4 weeks using IP laparoscopy-assisted aerosoliza-
tion (PIPAC).
Secondary end points include pharmacokinetic/pharmacody-
namic analysis, pathological response rate, surgical morbidity and
mortality of laparoscopy, quality of life at 2 and 6 months, and
technical failure rate.
Inclusion criteria
Patients with advanced, biopsy-proven PC from ovarian, breast, gas-
tric, hepatobiliary, or pancreatic origin. Concurrent systemic cancer
treatment with a taxane is not allowed. Detailed inclusion and exclu-
sion criteria can be found on clinicaltrials.gov/ct2/show/NCT03304210.
Experimental methods (Table 1)
Surgical procedure: Patients will undergo three PIPAC procedures
with an interval of 4 weeks. This interval is chosen in anticipation of
future randomized comparisons of systemic chemotherapy with or
without concurrent PIPAC, which can be added in week 4 of com-
monly used systemic therapy regimens. Each procedure will consist
of the following steps:
1. Exploration, peritoneal carcinomatosis index calculation, digital
imaging of the entire cavity
2. Punch biopsies in each abdominal quadrant (left fossa, right fossa,
left upper abdomen, and right upper abdomen), if disease is present
3. IP aerosol delivery of ABP; evacuation after 30 minutes using
the closed circuit. No electrostatic precipitation is used.
4. Pneumoperitoneum is re-established and four additional punch
biopsies taken, adjacent to the previous location. Biopsy sites
are marked with a clip (only during first PIPAC).
Dose escalation of albumin-bound paclitaxel: Dose levels of ABP will
be 35, 70, 90, 112.5, and 140mg/m². The same dose will be used for all
three treatments in the same patient. The estimated plasma half-life of
ABP ranges from 13 to 27 hours.
Additional and translational end points:
– Pharmacokinetic analysis: Plasma samples (5mL) will be col-
lected at the start of nebulization and 15, 30, and 60 min and
1.5, 2, 4, 8, 12, and 24 h after each PIPAC procedure. Drug con-
centrations will be measured using ultra-performance liquid
chromatography–tandem mass spectrometry. Tumor tissue sam-
ples in each abdominal quadrant (n = 4 punch biopsies, approxi-
mately 8–10mm3) will be taken at the end of aerosol delivery after
each PIPAC procedure for tissue paclitaxel concentration
analysis.
– Pharmacodynamic (PD) analysis: Tumor tissue samples (punch
biopsies, approximately 8–10 mm3) will be taken in each abdom-
inal quadrant before (n= 4) and at the end (n= 4) of aerosol delivery
after each PIPAC procedure. Standard histology and immunohisto-
chemistry (caspase 3) will be performed on tissue biopsies.
– Plasma biomarkers of treatment response: Part of the plasma
samples (5mL) taken before surgery and at days 1 and 7 after
each PIPAC will be stored for exploratory biomarker analysis (cir-
culating tumor cells, circulating DNA, and extracellular vesicles).
– Quality of life: QLQ-C30 and Functional Assessment of Cancer
Therapy-General (FACT-G) questionnaires will be taken 1 day
before each PIPAC, 2 weeks after each PIPAC, and 2 and 6
months after the third PIPAC procedure.
– Postoperative pain score: Patients will be asked to score pain on
a visual analog scale 1 day before each PIPAC and at 8, 12, and
24 h and 1 week after each PIPAC procedure.
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Ethical approval
The study protocol was approved in its amended form by the Ethical
Committee of Ghent University Hospital, which acts as the central
Ethical Committee, on 6 April 2018 (ref 2017/0920). Approval by the
Ethical Committee of the other participating centers is pending.
Statistical considerations
In order to minimize the sample size, a Bayesian approach with con-
tinual reassessment will be used [10]. Conservative a priori estimates of
DLT (defined in Table 2) are used for initial simulation, resulting in a
moderate pace of escalation: 35–35–70–70–90–90–90–112.5–112.5–
112.5–140–140–140–140–140–140–140–140–140–140mg/m2. The max-
imal dose of 140mg/m2 is based on the finding that this was the MTD in
the study of Cristea et al. [9]. The provisional sample size is therefore 20,
but this is subject to recalculation.
Results and discussion
While IP drug delivery has been firmly established as a
treatment option in patients with PC, clinical treatment
has to rely on off-label use of drugs that were developed
and approved for systemic treatment. Therefore, develop-
ment of drugs or platforms that are specifically designed
for IP delivery is a priority. Theoretically, nanobodies
hold promise for IP delivery, due to their peritoneal
retention and the possibility to incorporate a variety of
targeted and untargeted payloads [11]. Albumin-based
nanoparticles are approved for systemic treatment of
cancer. It is rational to explore IP delivery of IP adminis-
tration of albumin-bound particles. First, cancers such as
ovarian and pancreatic cancers express high levels of
secreted protein acidic and rich in cysteine (SPARC/osteo-
nectin/BM40), an albumin-binding 42-kDa matricellular
glycoprotein, the expression of which correlates inversely
with outcome [12]. Also, macropinocytosis of ABP was
shown to drive macrophage activation in mouse models,
pointing to possible synergy with immunotherapy [13].
Other albumin-binding proteins and receptors that may
mediate tumor accumulation of albumin-bound carriers
include albondin (gp60), gp18, gp30, calreticulin, mega-
lin, cubilin, heterogeneous nuclear ribonucleoproteins
(hnRNPs), and the neonatal Fc receptor (FcRn) [14].
Preliminary data from animal models seem to con-
firm the potential of IP ABP administration. Coccolini
Table 1: Overview of experimental interventions.
Study period
Enrollment Allocation Postallocation Follow-up
Time point Preoperative  week 
week

weeks

weeks

weeks

weeks

weeks

weeks

weeks

weeks

weeks

weeks
Enrollment
Eligibility screen x
Informed consent x
Allocation x
Interventions
PIPAC  x
PIPAC  x
PIPAC  x
Assessments
Blood sampling
for toxicity
x x x x
Blood sampling
for PK
modelling
x x x
Tumor biopsies
for PK
modelling
x x x
Blood sampling
for PD
modelling
x x x x x x x
Quality of life x x x x x x
Pain score x x x x x x x
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and coworkers compared HIPEC with either ABP or cre-
mophor-based paclitaxel in a rabbit model and found
that ABP penetrated up to 0.63mm in the (healthy)
peritoneal wall, while the standard formulation was
not detectable in the peritoneum [8]. We have recently
demonstrated that IP ABP results in significant antitu-
mor efficacy in a mouse xenograft model of peritoneal
metastasis from ovarian origin (Carlier et al., manuscript
in preparation).
These considerations prompted us to explore the fea-
sibility and safety of PIPAC using ABP. Data from our lab
show that ABP remains structurally intact after nebuliza-
tion and after dilution (unpublished data). Systemic toxi-
city is expected to be limited, since Cristea et al., in a
phase I trial of IP instillation of ABP for advanced carci-
nomatosis, found a significant pharmacokinetic benefit
associated with IP delivery [9]. In order to limit the sample
size, we opted for a Bayesian approach, which consists of
continually reassessing the probability of toxicity based on
the prior toxicity observed. Once the present phase I trial is
completed, we plan to design randomized phase II trials in
selected indications (e.g., recurrent, platinum-resistant
epithelial ovarian cancer). In parallel, we will investigate
the mechanisms of albumin-mediated nanoparticle trans-
port mechanisms after IP delivery in vitro and in vivo.
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